Description
Research overview
About This Research Material
Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH), supplied here as a 10 mg lyophilized (freeze-dried) research peptide for in-vitro and preclinical laboratory work only. Structurally it is a stabilized 44-residue peptide corresponding to the full-length GHRH(1-44) sequence, distinguished from native GHRH by an N-terminal trans-3-hexenoyl (unsaturated fatty-acid) modification. This acylation is the defining feature of the molecule in the research literature: it hinders recognition by dipeptidyl peptidase-IV (DPP-IV), the enzyme that rapidly clips the N-terminus of unmodified GHRH, and thereby extends the peptide’s measurable half-life in experimental systems. Investigators frequently reference the compound by its development code TH9507.
As a GHRH-receptor agonist, Tesamorelin is studied in laboratory settings as a tool compound for probing the somatotroph axis at the level of the pituitary GHRH receptor, rather than as a direct agonist of the growth-hormone receptor itself. This mechanistic position, upstream at a G-protein-coupled receptor, is part of why it appears in receptor-pharmacology and secretagogue research alongside shorter fragments such as GHRH(1-29). The material offered on this page is intended solely as a characterized reference compound for that kind of controlled, benchtop investigation.
What Has Been Studied
The preclinical and in-vitro literature surrounding Tesamorelin centers on its interaction with the GHRH receptor and on the pharmacological consequences of its enzymatic stabilization. Reported research themes include the following, described strictly as observations in laboratory models rather than as outcomes in humans:
- Receptor-agonism studies: cell-based assays measuring GHRH-receptor engagement and downstream cyclic-AMP signaling in cultured pituitary-derived or receptor-transfected cell lines.
- Enzymatic stability comparisons: in-vitro work contrasting the degradation of the trans-3-hexenoyl-modified peptide with native GHRH in the presence of DPP-IV and serum, used to characterize the structural basis of its extended half-life.
- Secretagogue-axis modeling: preclinical model systems in which GHRH analogs are used as pharmacological probes of pulsatile somatotroph signaling.
- Analytical and formulation research: stability profiling of the lyophilized peptide across buffer systems and reconstitution conditions relevant to assay design.
Because experimental parameters such as cell type, receptor construct, concentration range, and endpoint differ substantially between reports, cross-study generalization is not supported by the current data. This research is preliminary and ongoing, and the information here is educational only and not medical advice. Researchers reviewing this literature typically treat it as mechanistic and hypothesis-generating. Observations in isolated cells or animal models do not establish results in other biological systems, and this material is not a therapeutic product.
Tesamorelin specifications
| Compound | Tesamorelin |
|---|---|
| CAS number | 218949-48-5 |
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5135.9 g/mol |
| Sequence | 44-residue GHRH(1-44) analog with an N-terminal trans-3-hexenoyl group |
| Form | Lyophilized (freeze-dried) powder |
| Vial contents | 10 mg |
| Purity & identity | Documented on the lot-specific Certificate of Analysis (HPLC purity, mass spectrometry identity) |
| Storage | −20 °C, sealed, dry, protected from light |
| Intended use | Laboratory and analytical research use only. Not for human or veterinary use. |
Storage and handling of lyophilized Tesamorelin
Store lyophilized material at −20 °C or below, sealed, dry, and protected from light. Short-term storage at 2–8 °C is generally acceptable. Allow the sealed vial to reach room temperature before opening to limit moisture condensation, and minimize repeated temperature cycling.
Frequently asked questions
What is the CAS number of Tesamorelin?
The CAS Registry Number for Tesamorelin is 218949-48-5. (The acetate salt form is registered separately as 901758-09-6.)
What is the molecular weight of Tesamorelin?
Tesamorelin has a molecular formula of C221H366N72O67S and an average molecular weight of 5135.9 g/mol.
How should lyophilized Tesamorelin be stored?
Store lyophilized material at −20 °C or below, sealed, dry, and protected from light. Short-term storage at 2–8 °C is generally acceptable. Allow the sealed vial to reach room temperature before opening to limit moisture condensation, and minimize repeated temperature cycling.
Is a Certificate of Analysis available for Tesamorelin?
Yes. Each lot is documented with a lot-specific Certificate of Analysis covering identity and purity. Published certificates are listed in our COA Library, searchable by product or lot number.
Is Tesamorelin intended for human or veterinary use?
No. Tesamorelin is sold strictly for laboratory, analytical, and scientific research. It is not intended for human or veterinary use, diagnosis, or treatment. See our Research Disclaimer.
